Research Overview
· Last Reviewed May 3, 2026· PSI Editorial Board· IndependentCan Peptides Treat Erectile Dysfunction?
The honest map across 8 ED scenarios — etiology, what's been studied, and where validated PDE5 inhibitors and alprostadil rule.
WHICH ED CONTEXT?
ED Context
Animal Studies
Human Trials
Vasculogenic ED (organic)
endothelial dysfunction etiology
ED from low testosterone
hypogonadism contributing
Psychogenic ED
psychological etiology
Post-prostatectomy ED
nerve-sparing surgery context
Diabetic ED
vascular + neuropathic
ED as cardiovascular sentinel
ASCVD risk assessment
Refractory ED (failed PDE5i)
second-line therapy
Adjunct alongside PDE5i
off-label combination context
How counts are scaled → · Tap any row to see the studies →
Quick Answer
Erectile dysfunction has well-characterized validated approaches in clinical practice. Foundations include comprehensive evaluation by urology or primary care. Workup covers cardiovascular risk assessment, hormone testing (testosterone, prolactin, TSH), and individualized therapy matching per AUA guidelines. Validated FDA-approved options include PDE5 inhibitors (sildenafil/Viagra, tadalafil/Cialis, vardenafil/Levitra, avanafil/Stendra) as first-line. None of these is a peptide on this page.
Bremelanotide (PT-141) is FDA-approved as Vyleesi for premenopausal female HSDD only. Off-label male ED use exists in some men's health clinic contexts but lacks Phase 3 outcome evidence comparable to PDE5 inhibitors.
HCG is FDA-approved for male hypogonadotropic hypogonadism with relevance when low testosterone contributes to ED. The compound stimulates endogenous testosterone production via LH-receptor activation.
Tesamorelin holds FDA approval for HIV-associated lipodystrophy with limited cardiometabolic adjacent context relevant to ED-as-cardiovascular-sentinel framing.
Oxytocin has intimacy and relationship research with mixed effect sizes and absent ED-specific evidence.
The honest framing: no peptide is FDA-approved for male ED. PDE5 inhibitors are validated first-line. For hypogonadism-related ED, HCG and testosterone replacement are validated. For broader context, see Peptides for Sexual Health and Peptides for Testosterone Support.
Bremelanotide off-label vs PDE5 inhibitors for ED
Off-label peptide use vs FDA-approved validated standard-of-care
PDE5 inhibitors hold FDA approvals for erectile dysfunction with substantial Phase 3 evidence. Sildenafil (Viagra) was FDA-approved in 1998. Tadalafil (Cialis) followed with longer half-life and daily-dosing option. Vardenafil (Levitra) and avanafil (Stendra) provide additional options. The class has decades of safety data and represents the validated first-line for organic ED. Mechanism is direct phosphodiesterase-5 inhibition with enhanced penile blood flow.
Bremelanotide is FDA-approved as Vyleesi for premenopausal female HSDD only. Off-label male ED use exists despite no FDA approval for male ED indication. Mechanism is melanocortin-4 receptor agonism with central sexual desire pathway activation. Phase 3 outcome trial evidence in male ED specifically is limited. Early intranasal Phase 2 studies in men with ED were not pursued to Phase 3; pivotal evidence focused on female HSDD subcutaneous administration.
PSI's reading: for male ED, PDE5 inhibitors are the validated FDA-approved first-line with substantial Phase 3 evidence. Bremelanotide off-label male use is not validated practice. Patients with ED should work with urology or primary care on PDE5 inhibitor evaluation, alprostadil if needed, vacuum erection devices, testosterone replacement if hypogonadism is present, and surgical options for refractory cases.
HCG for ED secondary to hypogonadism
Validated approach when low testosterone contributes
Hypogonadism contributes to ED in a subset of men. The relationship is bidirectional. Low testosterone reduces libido and can affect erectile function. ED prompts evaluation that may identify underlying hypogonadism. Endocrine Society guidelines recommend testosterone therapy in men with documented hypogonadism and symptoms including ED. Testosterone restoration improves sexual function in this subset. PDE5 inhibitors typically remain part of comprehensive treatment.
HCG holds FDA approval for male hypogonadotropic hypogonadism. The compound stimulates endogenous testosterone production via LH-receptor activation, preserving testicular volume and supporting fertility. When ED is secondary to documented hypothalamic or pituitary hypogonadism, HCG can be appropriate validated therapy. Comprehensive workup is essential before initiation. ED with normal testosterone does not benefit from HCG.
PSI's reading: for ED secondary to documented hypogonadism, HCG is a validated FDA-approved option that preserves fertility. Exogenous testosterone replacement is also FDA-approved with different mechanism. HCG and exogenous TRT can be combined or chosen individually based on fertility preservation goals. PDE5 inhibitors remain part of comprehensive ED treatment regardless of testosterone-axis intervention.
Validated ED treatment ladder vs research peptides
Where peptides fit alongside the broader ED toolkit
Validated ED treatment ladder begins with comprehensive evaluation. Cardiovascular risk assessment, hormone testing, mental health and relationship factors, and cardiovascular workup when indicated all matter. ED is increasingly recognized as a cardiovascular sentinel. PDE5 inhibitors are first-line FDA-approved therapy. Alprostadil intracavernosal injection or intraurethral suppository is second-line. Vacuum erection devices provide non-pharmacologic option. Testosterone replacement addresses hypogonadism contribution. Penile implants are validated for refractory cases. Sex therapy through AASECT-certified therapists addresses psychogenic factors.
Lifestyle interventions are foundational. Cardiovascular risk factor management, weight management, regular exercise, adequate sleep, stress management, limited alcohol, and treatment of comorbid sleep apnea all have validated evidence for ED prevention and improvement. Treatment of underlying conditions including depression and metabolic syndrome provides additional benefit.
PSI's reading: validated FDA-approved ED treatment dominates. Peptides on this page are not validated alternatives to PDE5 inhibitors, alprostadil, vacuum devices, or penile implants. HCG has validated role specifically when ED is secondary to documented hypogonadism. Off-label peptide use without FDA-approved indication evidence is not validated ED practice. Patients with ED benefit from urology evaluation before considering off-label peptide therapy.
ED as cardiovascular sentinel — comprehensive workup
Beyond pharmacotherapy to cardiovascular health
ED is increasingly recognized as a cardiovascular sentinel. Endothelial dysfunction, the underlying pathophysiology of vasculogenic ED, often precedes overt cardiovascular events by 3-5 years. New ED diagnosis warrants cardiovascular risk assessment including blood pressure, lipid panel, glucose or HbA1c, and ASCVD risk calculation. Patients with ED and cardiovascular risk factors benefit from cardiology evaluation when indicated. Treatment of cardiovascular risk factors improves both overall cardiovascular outcomes and ED.
Comprehensive cardiometabolic optimization includes Mediterranean dietary pattern, regular aerobic exercise, resistance training, weight management, sleep optimization, stress management, and treatment of comorbid sleep apnea. Statin therapy when indicated for cardiovascular risk reduction may improve endothelial function and ED. Diabetes management improves both glycemic and erectile outcomes.
PSI's reading: ED diagnosis is an opportunity for comprehensive cardiometabolic evaluation. Tesamorelin's narrow HIV-lipodystrophy approval does not extend to general cardiometabolic indication or ED specifically. Validated cardiovascular risk reduction and ED-specific therapy work together. Cardiology, primary care, urology, and endocrinology coordinate comprehensive care. Off-label peptide use does not substitute for validated cardiovascular and ED management.
The Compounds, Ranked by Evidence
Ordered by strength of controlled human data, not popularity.
Of the 4 peptides discussed for erectile dysfunction, none holds FDA approval for male ED. Bremelanotide holds FDA approval as Vyleesi for premenopausal female HSDD only. Off-label male ED use lacks Phase 3 evidence. HCG holds FDA approval for male hypogonadotropic hypogonadism with secondary relevance when low testosterone contributes to ED. Tesamorelin holds FDA approval for HIV-lipodystrophy with limited cardiometabolic adjacent context. Oxytocin sexual health use is research-grade. Validated FDA-approved ED treatment dominates: PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil), alprostadil intracavernosal and intraurethral, vacuum erection devices, testosterone replacement when hypogonadism is present, penile implants for refractory cases, and sex therapy for psychogenic factors.
HCG
FDA-approved for male hypogonadotropic hypogonadism with validated role when ED is secondary to documented low testosterone. Preserves fertility.
Counts are PubMed-indexed papers and registered clinical trials. Scale: Strong 10+, Moderate 4–9, Limited 1–3, None 0. Methodology →
| Context | Animal Studies | Human Trials |
|---|---|---|
Male hypogonadotropic hypogonadism FDA-approved indication | 8 Strong LH-receptor activation evidence in testicular function models. | 6 Substantial Phase 3 evidence supporting FDA approval; testosterone restoration with effects on sexual function when hypogonadism is the etiology. Liu 2009 |
ED secondary to hypogonadism validated when low testosterone contributes | 6 Testosterone restoration effects on male sexual function in animal models. | 4 Endocrine Society guidelines support testosterone therapy effects on sexual function in documented hypogonadism. Bhasin 2018 |
Bremelanotide (PT-141)
FDA-approved Vyleesi for premenopausal female HSDD only. Off-label male ED use lacks Phase 3 evidence comparable to PDE5 inhibitors.
| Context | Animal Studies | Human Trials |
|---|---|---|
Premenopausal female HSDD FDA-approved Vyleesi indication | 6 Melanocortin receptor agonist effects on sexual behavior in animal models. | 6 Phase 3 RECONNECT trials supporting 2019 FDA approval. Kingsberg 2019 |
Off-label male ED off-label use without Phase 3 evidence | 4 Some animal evidence for male sexual function effects. | 2 Early Phase 2 intranasal studies in men with ED; subcutaneous off-label use lacks Phase 3 evidence. Diamond 2004 |
Tesamorelin
FDA-approved for HIV-associated lipodystrophy. Limited cardiometabolic adjacent context. Absent ED-specific evidence.
| Context | Animal Studies | Human Trials |
|---|---|---|
HIV-associated lipodystrophy FDA-approved indication | 6 GHRH analog effects on body composition in animal models. | 6 Phase 3 trials supporting FDA approval; visceral fat reduction with cardiometabolic improvements. Falutz 2007 |
ED context (off-label) absent ED-specific evidence | 0 No animal evidence specific to ED. | 0 No human ED-specific trials. PDE5 inhibitors are validated FDA-approved ED first-line. |
Oxytocin
FDA-approved for peripartum obstetric only. Mixed intimacy research with absent ED-specific Phase 3 evidence.
| Context | Animal Studies | Human Trials |
|---|---|---|
Peripartum obstetric FDA-approved indication | 6 Uterine contractile effects in animal models. | 8 Substantial Phase 3 evidence supporting Pitocin FDA approval for labor and postpartum hemorrhage. |
ED (off-label) absent ED-specific evidence | 0 No animal evidence specific to ED. | 0 No human ED-specific trials. Walum 2018 |
What's Marketed vs What's Studied
6 common claims, corrected.
“Peptides are a safer alternative to PDE5 inhibitors for ED.”
PDE5 inhibitors are FDA-approved for ED with decades of safety data and substantial Phase 3 evidence. No peptide on this page is FDA-approved for male ED. Bremelanotide off-label male ED use exposes patients to side effects (nausea, flushing, cardiovascular caution) without validated efficacy. PDE5 inhibitor contraindications are well-characterized; absolute contraindication is concurrent nitrate use.
“Bremelanotide (PT-141) is FDA-approved for male erectile dysfunction.”
Bremelanotide (Vyleesi) is FDA-approved exclusively for premenopausal female HSDD acquired and not due to medical or psychiatric condition. Off-label male ED use exists but is not FDA-approved and lacks Phase 3 outcome evidence comparable to PDE5 inhibitors.
“PT-141 works through enhanced penile blood flow like Viagra.”
Bremelanotide acts through central nervous system melanocortin-4 receptor agonism affecting sexual desire pathways. PDE5 inhibitors act through peripheral phosphodiesterase-5 inhibition enhancing penile blood flow. The mechanisms are different. The clinical evidence comparison does not support equivalent positioning for organic ED.
“HCG fixes ED in any man with low energy.”
HCG is FDA-approved for documented hypogonadotropic hypogonadism. ED with normal testosterone does not benefit from HCG. Comprehensive hormone workup including total testosterone, free testosterone, LH, FSH, prolactin, and SHBG is essential before testosterone-axis intervention. PDE5 inhibitors remain first-line for ED regardless of testosterone status.
“Tesamorelin improves ED through cardiometabolic effects.”
Tesamorelin is FDA-approved for HIV-associated lipodystrophy specifically. ED-specific Phase 3 evidence is absent. Cardiometabolic optimization for ED through validated approaches (lifestyle, statins, antihypertensives, glycemic control) is appropriate; Tesamorelin off-label use is not part of this validated framework.
“I can self-treat ED with peptides without seeing a doctor.”
ED is increasingly recognized as a cardiovascular sentinel. New ED diagnosis warrants cardiovascular risk assessment, hormone testing, and comprehensive evaluation. Self-treatment with off-label peptides bypasses essential clinical workup. Validated FDA-approved options including PDE5 inhibitors require prescriber evaluation.
If Considering Use, Here Is How to Be Safe
How to evaluate sources, verify quality, and find qualified physicians.
Get comprehensive ED evaluation.
Cardiovascular risk assessment, hormone testing (testosterone, prolactin, TSH), mental health screening, and individualized therapy matching guide treatment decisions per AUA guidelines.
Establish urology or primary care specialty.
Urology handles complex ED, refractory cases, second-line therapy, and surgical options. Primary care manages uncomplicated cases. Endocrinology handles hypogonadism workup.
Match FDA-approved options to your etiology.
PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) are validated first-line. Alprostadil for second-line. HCG when hypogonadism contributes. Penile implants for refractory cases.
Consider cardiovascular workup.
ED is a cardiovascular sentinel. Endothelial dysfunction often precedes cardiovascular events. Comprehensive cardiometabolic optimization is foundational alongside ED treatment.
Optimize lifestyle and validated foundations.
Cardiovascular risk factor management, weight management, regular exercise, adequate sleep, stress management, limited alcohol, and treatment of comorbid sleep apnea form the validated foundation.
Approach off-label peptide use cautiously.
Bremelanotide off-label male ED use lacks Phase 3 evidence. Tesamorelin and Oxytocin lack ED-specific evidence. HCG has validated role specifically when ED is secondary to documented hypogonadism.
The regulatory landscape for ED is dynamic. PDE5 inhibitors remain validated FDA-approved first-line with multiple branded and generic options. Bremelanotide (Vyleesi) FDA approval is limited to female HSDD. Compounded peptides face regulatory scrutiny. PSI tracks these developments and updates this page as material changes occur.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Common Questions
Are any peptides FDA-approved for erectile dysfunction?
No. None of the four peptides on this page is FDA-approved for male erectile dysfunction in the United States. Bremelanotide (Vyleesi) is FDA-approved for premenopausal female HSDD only. HCG is FDA-approved for male hypogonadotropic hypogonadism, fertility, and prepubertal cryptorchidism, not ED specifically. Tesamorelin is FDA-approved for HIV-associated lipodystrophy. Oxytocin is FDA-approved for peripartum obstetric indications. PDE5 inhibitors (sildenafil/Viagra, tadalafil/Cialis, vardenafil/Levitra, avanafil/Stendra) are FDA-approved for ED but are small molecules, not peptides.
Should I see a urologist for erectile dysfunction?
Yes. ED warrants comprehensive evaluation that benefits from urology specialty involvement. Urology handles complex ED, refractory cases, second-line therapy (alprostadil intracavernosal/intraurethral), and surgical options (penile implants). Primary care can manage initial ED assessment and PDE5 inhibitor prescription for uncomplicated cases. Endocrinology specialty handles hypogonadism workup. ED is increasingly recognized as a cardiovascular sentinel. Mental health and sex therapy address psychogenic factors.
What is the strongest validated treatment for ED?
PDE5 inhibitors are the FDA-approved first-line for ED with substantial Phase 3 evidence and decades of safety data. Options include sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra). The class differs in onset, duration, and side-effect profiles. Tadalafil offers daily-dosing option for chronic management. Patient selection considers cardiovascular contraindications including nitrate use. Additional validated options include alprostadil (intracavernosal/intraurethral), vacuum erection devices, testosterone replacement when hypogonadism is present, and penile implants for refractory cases.
What about Bremelanotide (PT-141) for male ED?
Bremelanotide is FDA-approved as Vyleesi for premenopausal female HSDD only. Off-label male ED use exists in some men's health clinic and integrative medicine contexts but is not FDA-approved and lacks Phase 3 outcome evidence comparable to PDE5 inhibitor evidence base. Mechanism is melanocortin-4 receptor agonism with central sexual desire pathway activation rather than peripheral hemodynamic effects. Common side effects include nausea, flushing, and transient blood pressure elevation. The compound carries cardiovascular cautions. PDE5 inhibitors remain validated first-line for ED.
Can HCG help with ED secondary to low testosterone?
Yes when ED is secondary to documented hypogonadotropic hypogonadism. HCG is FDA-approved for male hypogonadotropic hypogonadism and stimulates endogenous testosterone production via LH-receptor activation. The compound preserves testicular volume and supports fertility. Comprehensive workup including total testosterone, free testosterone, LH, FSH, prolactin, and SHBG is essential before initiation. ED with normal testosterone does not benefit from HCG. PDE5 inhibitors remain part of comprehensive ED treatment regardless of testosterone-axis intervention.
Is ED a sign of cardiovascular disease?
ED is increasingly recognized as a cardiovascular sentinel. Endothelial dysfunction underlying vasculogenic ED often precedes overt cardiovascular events by 3-5 years. New ED diagnosis warrants cardiovascular risk assessment including blood pressure, lipid panel, glucose or HbA1c, and ASCVD risk calculation. Patients with ED and cardiovascular risk factors benefit from cardiology evaluation when indicated. Treatment of cardiovascular risk factors improves both overall cardiovascular outcomes and ED. Statin therapy and diabetes management may improve both.
What if PDE5 inhibitors don't work for me?
PDE5 inhibitor failure (refractory ED) warrants urology evaluation. Second-line FDA-approved options include alprostadil (Caverject, Edex intracavernosal injection; MUSE intraurethral suppository) and vacuum erection devices. Combination therapy is sometimes used. Testosterone-axis evaluation is appropriate. Penile implants are validated for refractory cases. Cardiovascular workup and mental health/sex therapy address contributing factors. Off-label peptide use is not part of validated refractory-ED treatment ladder.
Can lifestyle changes improve ED?
Yes. Multiple lifestyle interventions have substantial validated evidence for ED prevention and improvement. Cardiovascular risk factor management protects erectile function. Weight management improves ED. Regular aerobic exercise improves cardiovascular fitness and erectile function. Resistance training supports overall health and testosterone status. Adequate sleep optimizes testosterone production. Stress management addresses psychogenic factors. Limited alcohol consumption reduces ED risk. Treatment of comorbid sleep apnea improves erectile function.
What about post-prostatectomy ED?
Post-prostatectomy ED is common after radical prostatectomy even with nerve-sparing technique. Validated approaches include early initiation of PDE5 inhibitors (penile rehabilitation), alprostadil intracavernosal or intraurethral, vacuum erection devices, and penile implants for refractory cases. Recovery timeline varies and can extend 12-24 months after surgery. Couples counseling addresses relationship factors during recovery. Off-label peptide use is not part of validated post-prostatectomy ED management.
How does diabetes affect ED?
Diabetes increases ED risk substantially through combined vascular and neuropathic mechanisms. Diabetic ED often responds less robustly to PDE5 inhibitors than non-diabetic ED. Comprehensive diabetes management including glycemic control improves erectile outcomes. Cardiovascular risk factor management is particularly important. Validated ED treatments apply with diabetes-specific considerations. Endocrinology and urology coordination ensures comprehensive care. Off-label peptide use without diabetes-specific ED evidence is not validated practice.
Are these peptides legal in the United States?
Bremelanotide is FDA-approved as Vyleesi commercial product for female HSDD only by prescription. HCG is FDA-approved with multiple commercial products by prescription for hypogonadism, fertility, and cryptorchidism. Tesamorelin is FDA-approved as Egrifta for HIV-lipodystrophy by prescription. Oxytocin is FDA-approved for obstetric indications. None is FDA-approved for male ED specifically. Compounded peptides for off-label ED use are available through 503A pharmacies but represent non-validated practice. PDE5 inhibitors are FDA-approved by prescription as validated ED first-line.
What are the side effects of off-label peptides for ED?
Bremelanotide common side effects include nausea (often dose-limiting), flushing, injection site reactions, headache, and transient blood pressure elevation. Vyleesi labeling carries explicit cardiovascular cautions and contraindication in uncontrolled hypertension. HCG side effects include injection site reactions, headache, mood changes, and gynecomastia in men with high-dose use. Tesamorelin side effects include injection site reactions and IGF-1 elevations. Oxytocin obstetric IV side effects can include cardiovascular effects. PDE5 inhibitors have well-characterized side-effect profiles.
Should I consider sex therapy for ED?
Yes when psychogenic factors contribute to ED. Psychogenic ED includes performance anxiety, depression-related ED, relationship factors, and sexual trauma history. Sex therapy through AASECT-certified therapists addresses these factors alongside pharmacotherapy. Couples therapy may be appropriate. Performance anxiety often responds well to PDE5 inhibitor pharmacotherapy combined with cognitive-behavioral approaches. The American Association of Sexuality Educators, Counselors and Therapists (AASECT) certifies sex therapists. Sex therapy is foundational alongside any pharmacotherapy for ED with psychological contributors.
What questions should I ask a doctor about ED?
Ask: (1) What is my comprehensive ED evaluation including cardiovascular risk assessment and hormone testing? (2) For my specific etiology (vasculogenic, hormonal, neurogenic, psychogenic, or mixed), what FDA-approved options apply? (3) Should I start with PDE5 inhibitors, and do I need cardiology workup first? (4) Have I optimized lifestyle foundations? (5) If hypogonadism is identified, should I consider HCG or testosterone replacement? (6) Should I consider sex therapy through an AASECT-certified therapist? (7) How do contraindications apply (PDE5 inhibitors with nitrates)?
Is ED common in younger men?
ED in younger men (under 40) is more common than historically recognized. Causes often include psychogenic factors (performance anxiety, depression, relationship stress), early cardiovascular risk factors, hormonal causes, medication side effects (SSRIs, beta-blockers, finasteride), substance use including alcohol and recreational drugs, and chronic conditions including diabetes. Comprehensive evaluation by urology or primary care including cardiovascular risk assessment is appropriate. Performance anxiety often responds well to PDE5 inhibitor pharmacotherapy combined with cognitive-behavioral approaches and sex therapy. Hormone testing identifies hypogonadism contribution. Lifestyle optimization including sleep, exercise, and stress management has substantial evidence in younger men with ED.
How soon after starting ED treatment will I see results?
Treatment timelines vary by approach. PDE5 inhibitors work within 30-60 minutes for sildenafil and avanafil with 4-6 hour duration. Tadalafil works within 30-60 minutes with 36-hour duration enabling daily-dosing options. Vardenafil works within 30-60 minutes with 4-6 hour duration. Alprostadil intracavernosal injection produces erection within 5-20 minutes. HCG and testosterone replacement effects on testosterone develop over weeks to months. Sex therapy and lifestyle interventions show benefit over weeks to months. Comprehensive ED treatment typically requires 4-12 week assessment combining pharmacotherapy with lifestyle changes. Quick-fix expectations are not realistic for ED with multiple contributing factors.
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.